{"title":"ForumSpace","authors":"Abeer A. Ahmad, C. Choi, Lynaea Filbey, R. Zheng","doi":"10.15173/m.v1i37.2501","DOIUrl":"https://doi.org/10.15173/m.v1i37.2501","url":null,"abstract":"ForumSpace","PeriodicalId":22813,"journal":{"name":"The Meducator","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85429874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tau and beta-amyloid in Alzheimer’s disease: Theories, treatments strategies, and future directions
阿尔茨海默病中的Tau和β -淀粉样蛋白:理论、治疗策略和未来方向
{"title":"Tau and beta-amyloid in Alzheimer’s Disease: Theories, treatments strategies, and future directions","authors":"Jake Colautti, Kien Nagales","doi":"10.15173/M.V1I37.2502","DOIUrl":"https://doi.org/10.15173/M.V1I37.2502","url":null,"abstract":"Tau and beta-amyloid in Alzheimer’s disease: Theories, treatments strategies, and future directions","PeriodicalId":22813,"journal":{"name":"The Meducator","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72999384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Viruses in the Modern World","authors":"M. Moshkovich, Sophie Zarb","doi":"10.15173/M.V1I37.2505","DOIUrl":"https://doi.org/10.15173/M.V1I37.2505","url":null,"abstract":"","PeriodicalId":22813,"journal":{"name":"The Meducator","volume":"146 1","pages":"22-24"},"PeriodicalIF":0.0,"publicationDate":"2020-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78887146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Animal-assisted activities: Justifying a mental health program at McMaster University
动物辅助活动:麦克马斯特大学心理健康项目的合理性
{"title":"Animal-assisted activities: Justifying a mental health program at McMaster University","authors":"T. Li, Leland Cheung, Jeff Zhang","doi":"10.15173/M.V1I37.2503","DOIUrl":"https://doi.org/10.15173/M.V1I37.2503","url":null,"abstract":"\u0000 \u0000 \u0000 \u0000Animal-assisted activities: Justifying a mental health program at McMaster University \u0000 \u0000 \u0000 \u0000","PeriodicalId":22813,"journal":{"name":"The Meducator","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82103904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dr. Gordon Guyatt is a Distinguished Professor in the Department of Health Research Methods, Evidence, and Impact at McMaster University, and is one of the founders of “evidence-based medicine.” He has played a significant role in over 30 major clinical studies, including large-scale observational and randomized trials and has extensive expertise in study methodology. As the co-founder and co-chair of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group, he has been intimately involved in the development and evolution of the GRADE approach for evaluating research evidence.
Gordon Guyatt博士是麦克马斯特大学健康研究方法、证据和影响系的杰出教授，也是“循证医学”的创始人之一。他在30多项主要临床研究中发挥了重要作用，包括大规模观察性和随机试验，并在研究方法方面拥有广泛的专业知识。作为建议分级评估、发展和评估(GRADE)工作组的联合创始人和联合主席，他密切参与了用于评估研究证据的GRADE方法的发展和演变。
{"title":"Evidence-based Medicine (Dr. Gordon Guyatt)","authors":"D. Rayner, Hargun Kaur","doi":"10.15173/m.v1i36.2336","DOIUrl":"https://doi.org/10.15173/m.v1i36.2336","url":null,"abstract":"Dr. Gordon Guyatt is a Distinguished Professor in the Department of Health Research Methods, Evidence, and Impact at McMaster University, and is one of the founders of “evidence-based medicine.” He has played a significant role in over 30 major clinical studies, including large-scale observational and randomized trials and has extensive expertise in study methodology. As the co-founder and co-chair of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group, he has been intimately involved in the development and evolution of the GRADE approach for evaluating research evidence.","PeriodicalId":22813,"journal":{"name":"The Meducator","volume":"9 1","pages":"26-28"},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78282593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kashyap Patel, Omaike Sikder, Nikhil Nair Hariharan, Jeff Zhang
Pyruvate kinase (PK) is an enzyme involved in ATP production in the glycolytic pathway. PK deficiency is a rare, autosomal recessive disorder that manifests with hemolytic anemia of variable severity, partly due to an insufficiency of ATP production in erythrocytes. Its exact prevalence is unknown due to lack of awareness and challenges in making the diagnosis of PK deficiency. Current treatments for PK deficiency include blood transfusion and splenectomy, which focus on temporarily alleviating anemia and reducing hemolysis, respectively. Due to the rarity of this condition and its variable severity, a systematic treatment protocol for novel therapies is difficult to compile and validate. Oral administration of mitapivat, an allosteric activator of erythrocyte PK, is a novel treatment. Despite its promising effects on the hemoglobin levels in PK deficient patients, mitapivat’s efficacy and safety profiles must be determined through randomized controlled trials.
{"title":"Pyruvate Kinase Deficiency and Developments In its Treatment","authors":"Kashyap Patel, Omaike Sikder, Nikhil Nair Hariharan, Jeff Zhang","doi":"10.35493/medu.36.18","DOIUrl":"https://doi.org/10.35493/medu.36.18","url":null,"abstract":"Pyruvate kinase (PK) is an enzyme involved in ATP production in the glycolytic pathway. PK deficiency is a rare, autosomal recessive disorder that manifests with hemolytic anemia of variable severity, partly due to an insufficiency of ATP production in erythrocytes. Its exact prevalence is unknown due to lack of awareness and challenges in making the diagnosis of PK deficiency. Current treatments for PK deficiency include blood transfusion and splenectomy, which focus on temporarily alleviating anemia and reducing hemolysis, respectively. Due to the rarity of this condition and its variable severity, a systematic treatment protocol for novel therapies is difficult to compile and validate. Oral administration of mitapivat, an allosteric activator of erythrocyte PK, is a novel treatment. Despite its promising effects on the hemoglobin levels in PK deficient patients, mitapivat’s efficacy and safety profiles must be determined through randomized controlled trials.","PeriodicalId":22813,"journal":{"name":"The Meducator","volume":"41 1","pages":"18-21"},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74299229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Translocation INTRODUCTION Three-dimensional (3D) printing involves the creation of a 3D product through combining and depositing materials (i.e. plastic, metals, and ceramics) in layers.1 Since the first patent was made by Charles Hull in 1984, advances in 3D printing technology have allowed it to be utilized in a variety of fields, including engineering and medicine.2 Specifically, 3D printing technology has been useful in refining surgical techniques. 3D-printed anatomical models, surgical implants, and prosthetic limbs have proven to be beneficial in daily medical practice. Organ resection, reconstruction surgeries, reparative procedures, and organ transplantations have also been improved through this technology.1,2,3 3D PRINTING IN SURGERY AND MEDICINE
{"title":"3D Printing in Surgery and Medicine","authors":"A. Wong, Albert Stancescu, Michelle L. Chen","doi":"10.35493/medu.36.8","DOIUrl":"https://doi.org/10.35493/medu.36.8","url":null,"abstract":"Translocation INTRODUCTION Three-dimensional (3D) printing involves the creation of a 3D product through combining and depositing materials (i.e. plastic, metals, and ceramics) in layers.1 Since the first patent was made by Charles Hull in 1984, advances in 3D printing technology have allowed it to be utilized in a variety of fields, including engineering and medicine.2 Specifically, 3D printing technology has been useful in refining surgical techniques. 3D-printed anatomical models, surgical implants, and prosthetic limbs have proven to be beneficial in daily medical practice. Organ resection, reconstruction surgeries, reparative procedures, and organ transplantations have also been improved through this technology.1,2,3 3D PRINTING IN SURGERY AND MEDICINE","PeriodicalId":22813,"journal":{"name":"The Meducator","volume":"74 1","pages":"8-9"},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81138224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：